The intrinsic activity of (-)-3-PPP vis-a-vis prolactin-suppressing dopamine D2 receptors in transfected GH4C1 cells is dependent on which secretagogue that is used to provoke prolactin release

Neuropharmacology

Volumn 37, Issue 2, 1998, Pages 233-242

  Nilsson, Christer L ^a   Hellstrand, Monika ^a   Ekman, Agneta ^a   Eriksson, Elias ^a  

^a Inst Physiol Pharmacol G   (Sweden)

Author keywords

( ) 3 PPP; Dopamine; Dopamine D2 receptors; Full and partial agonism; Intrinsic activity; Prolactin secretagogues

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL; DOPAMINE 2 RECEPTOR; POTASSIUM; PRECLAMOL; PROLACTIN; PROTIRELIN; RACLOPRIDE; TETRYLAMMONIUM; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BINDING AFFINITY; CELL CULTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROTEIN BINDING; RECEPTOR BINDING;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; CELL LINE; DOPAMINE; DOPAMINE AGONISTS; HUMANS; PIPERIDINES; POTASSIUM; PROLACTIN; RECEPTORS, DOPAMINE D2; TETRAETHYLAMMONIUM; THYROTROPIN-RELEASING HORMONE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032004180     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00006-9     Document Type: Article

References (69)

1. 2 receptor to inhibition of adenylyl cyclase and prolactin secretion. J. Biol. Chem. 265:1990;2098-2104.
2. 1 cells. Biochem. Biophys. Res. Commun. 193:1993;801-807.
3. Baertschi A.J., Audigier Y., Lledo P.-M., Israel J.-M., Bockaert J., Vincent J.-D. Dialysis of lactotropes with antisense oligonucleotides assigns guanine nucleotide binding protein subtypes to their channel effectors. Mol. Endocrinol. 6:1992;2257-2265.
4. 1a autoreceptor-mediated inhibition of neurotransmitter synthesis: Relationship to receptor reserve. Neuropharmacology. 31:1992;451-459.
5. 3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem. Soc. Trans. 24:1996;57S.
6. αo in rat frontal cortex. FEBS Lett. 370:1995;135-140.
7. Canonico P.L., Jarvis W.D., Judd A.M., MacLeod R.M. Dopamine does not attenuate phosphoinositide hydrolysis in rat anterior pituitary cells. J. Endocrinol. 110:1986;389-393.
8. Carlsson M., Carlsson A., Eriksson E. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. Eur. J. Pharmacol. 142:1987;39-43.
9. 2 receptors in rat lactotrophs. J. Physiol. 410:1989;251-265.
10. Chen, C., Zhang, J., Israel, J.-M., Clarke, I.J., Vincent, J.-D., 1993. Mechanism of the prolactin rebound after dopamine withdrawal in rat pituitary cells. Am. J. Physiol. 265 (Endocrinol. Metab. 28), E145-E152.
11. 2-adrenergic receptor. Mol. Pharmacol. 50:1996;662-669.
12. Clark D., Hjorth S., Carlsson A. Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J. Neural Transm. 62:1985;1-52.
13. Clark D., Salah R.S., Galloway M.P. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: Dependence on extracellular dopamine. Synapse. 8:1991;169-176.
14. Cronin, M.J., Myers, G.A., MacLeod, R.M., Hewlett, E.L., 1983. Pertussis toxin uncouples dopamine agonist inhibition of prolactin release. Am. J. Physiol. 244 (Endocrinol. Metab. 7), E499-E504.
15. De Lean, A., Munson, P.J., Rodbard, D., 1978. Simultaneous analysis of families of sigmoidal curves; application to bioassay, radioligand assay, and physiological dose-response curves, Am. J. Physiol. 235, E97-E102.
16. De Quijada M., Timmermans H.A.T., Lamberts S.W.J., MacLeod R.M. Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine. Endocrinology. 106:1978;702-706.
17. 2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ-treated male rats. Life Sci. 48:1991;311-320.
18. 2 receptor density measured in vitro and in vivo in EEDQ-treated rats. Life Sci. 48:1991;321-331.
19. 2 receptor agonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;152-157.
20. Enjalbert A., Musset F., Chénard C., Priam M., Kordon C., Heisler S. Dopamine inhibits prolactin secretion stimulated by the calcium channel agonist BAY-K-8644 through a pertussis toxin-sensitive G-protein in anterior pituitary cells. Endocrinology. 123:1988;406-412.
21. Eriksson E., Carlsson M., Clark D., Nilsson C., Svensson K. Compounds with selectivity for dopamine autoreceptors: effects on prolactin secretion in male and female rats. Clin. Neuropharmacol. 9:1986;226-228.
22. Fagin K.D., Neill J.D. The effect of dopamine on thyrotropin-releasing-hormone-induced prolactin secretion in vitro. Endocrinology. 109:1981;1835-1840.
23. Forget H., Painson J.-C., Drew R.T., Lagacé G., Collu R. MMQ cells: a model for evaluating the role of G-proteins in the modulation of prolactin release. Mol. Cell. Endocrinol. 93:1993;125-133.
24. Furchgott R.F., Bursztyn P. Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann. N.Y. Acad. Sci. 144:1967;882-899.
25. Gardner, B.R., Strange, P.G., 1996. On the quantification of receptor function and the molecular mechanisms of agonist action at G-protein linked receptors, Br. J. Pharmacol. 117 (suppl): 1P.
26. 1A receptor. Biochemistry. 33:1994;4283-4290.
27. 2 dopamine receptors inhibits protein kinase C activity in striatal synaptoneurosomes. J. Neurochem. 63:1994;169-176.
28. Giannattasio G., Spada A., Nicosia S., De Camilli P. Transduction of dopamine and vasoactive intestinal peptide signals in prolactin-secreting cells. Mena F., Valverde C., Orlando R. Prolactin Secretion: A Multidisciplinary Approach. 1984;187-208 Academic Press, New York.
29. Gordeladze J.O., Johansen P.W., Paulssen R.H., Paulssen E.J., Gautvik K.M. G-proteins: Implications for pathophysiology and disease. Eur. J. Endocrinol. 131:1994;557-574.
30. Guderman T., Kalkbrenner F., Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu. Rev. Pharmacol. Toxicol. 36:1996;429-459.
31. 2(444) receptor and antagonist/agonist binding ratios. Br. J. Pharmacol. 115:1995;1307-1313.
32. Hoyer D., Boddeke H.W.G.M. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol. Sci. 14:1993;270-275.
33. Ikeda S.R., Korn S.J. Influence of permeating ions on potassium channel block by external tetraethylammonium. J. Physiol. 486.2:1995;267-272.
34. i2. J. Neurochem. 64:1995;1614-1621.
35. Jasper J.J. Evolving concepts of partial agonism: The β-adrenergic receptor as a paradigm. Biochem. Pharmacol. 43:1992;119-130.
36. Judd A.M., MacLeod R.M. Dopamine receptor and adrenoceptor agonists inhibit prolactin release from MMQ cells. Eur. J. Pharmacol. 195:1991;101-106.
37. Kenakin T. Agonist-receptor efficacy II: Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16:1995;232-238.
38. Kenakin T. Receptor conformational induction versus selection: All part of the same energy landscape. Trends Pharmacol. Sci. 17:1996;190-191.
39. Kenakin T. The classification of seven transmembrane receptors in recombinant systems. Pharmacol. Rev. 48:1996;413-463.
40. 2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol. Pharmacol. 42:1992;432-438.
41. 4.4 receptors. Eur. J. Pharmacol. 301:1996;R11-R13.
42. 2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: Relationship to dopamine stimulation of tyrosine phosphorylations. J. Pharmacol. Exp. Therap. 267:1993;1573-1581.
43. 1 pituitary cells. J. Biol. Chem. 269:1994;13880-13886.
44. 2+ currents in rat anterior pituitary cells. Neuron. 8:1992;455-463.
45. 3 receptor-ligand interactions. Thesis, paper VII. Uppsala University, Uppsala, Sweden.
46. 2 dopaminergic inhibition of prolactin release in vivo and in vitro. J. Pharmacol. Exp. Therap. 257:1991;668-675.
47. Minneman K., Abel P. Relationship between alfa-adrenoceptor density and functional response of rat vas deferens: Studies with phenoxybenzamine. Naunyn-Schmiedeberg's Arch. Pharmacol. 327:1984;238-246.
48. i protein subtypes. J. Biol. Chem. 266:1991;23392-23398.
49. 1 cells. J. Neurochem. 62:1994;907-915.
50. Mulder A.H., Draper R., Smini P., Schoffelmeer A.N.M., Stoof J.C. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro. Eur. J. Pharmacol. 107:1985;291-297.
51. 2-receptor cDNA expressed in a mammalian cell line. Mol. Pharmacol. 36:1989;446-451.
52. 7). Eur. J. Pharmacol. 218:1992;205-211.
53. 2 receptors? J. Neural Transm. [General Section]. 92:1993;213-220.
54. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride and phenoxybenzamine. Neuropsychopharmacology. 15:1996;53-61.
55. Pascual J.M., Shieh C.C., Kirsch G.E., Brown A.M. Multiple residues specify external tetraethylammonium blockade of voltage-gated potassium channels. Biophys. J. 69:1995;428-434.
56. Paulssen E.J., Paulssen R.H., Haugen T.B., Gautvik K.M., Gordeladze J.O. Regulation of G-protein mRNA levels by thyroliberin, vasoactive intestinal peptide and somatostatin in prolactin-producing rat pituitary adenoma cells. Acta Physiol. Scand. 143:1991;195-201.
57. 3 rat pituitary tumour cells. Biochem. Pharmacol. 44:1992;471-477.
58. 3 rat pituitary tumour cells. Acta Physiol. Scand. 146:1992;511-518.
59. Pugsley T.A., Davis M.D., Akunne H.C., Cooke L.W., Whetzel S.Z., MacKenzie R.G., Shih Y.-H., van Leeuwen D.H., Demattos S.B., Georgic L.M., Caprathe B.W., Wright J.C., Jaen J.C., Wise L.D., Heffner T.G. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I: Neurochemical effects. J. Pharmacol. Exp. Therap. 274:1995;898-911.
60. Ray K.P., Wallis M. Involvement of calcium ions in dopamine inhibition of prolactin secretion from sheep pituitary cells. Mol. Cell. Endocrinol. 28:1982;691-703.
61. 2 dopamine receptors and calcium channels in lactotrophs from cycling female rats. Endocrinology. 135:1994;501-508.
62. Robb S., Cheek T.R., Hannan F.L., Hall L.M., Midgley J.M., Evans P.D. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. EMBO J. 13:1994;1325-1330.
63. 4 receptor-mediated inhibition of cyclic adenosine 3′,5′-monophosphate production does not affect prolactin regulation. Endocrinology. 138:1997;1871-1878.
64. 2 receptors. NeuroReport. 6:1995;329-332.
65. Sibley D.R., Monsma F.J. Jr., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35:1993;391-415.
66. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 365:1993;170-175.
67. 2 dopamine receptor expressed in MMQ cells. Biochem. Pharmacol. 46:1993;747-751.
68. Strader C.D., Candelore M.R., Hill W.S., Dixon R.A.F., Sigal I.S. A single amino acid substitution in the β-adrenergic receptor promotes partial agonist activity from antagonists. J. Biol. Chem. 264:1989;16470-16477.
69. 2 receptors. Mol. Cell. Endocrinol. 112:1995;153-157.